近日，“2023中国生物医药科技创新价值榜”系列榜单在中国上海正式发布，博沃生物凭借在疫苗领域出色的创新研发能力荣获“最具成长性疫苗企业TOP10”。
“2023中国生物医药科技创新价值榜”由上海市生物医药行业协会携手医耘科技共同发起，基于华医研究院成长性判断标准，结合问卷调研、访谈、数据汇总及数据核查等基本流程，遴选出当年度具有行业创新价值的企业，形成业内第三方客观评价的榜单。本次评选下设小分子创新药、生物药、中医药、疫苗、细胞基因治疗、创新器械、体外诊断、消费医疗、数字医疗、CXO、生物医药园区、金融服务机构12个系列。其中疫苗榜单主要聚焦传统疫苗、重组蛋白疫苗、载体疫苗与核酸疫苗赛道，可以最直接地体现我国疫苗创新成果的百花齐放，一批具有国际影响力、高成长性的疫苗企业正以自身努力为我国疾病防控添砖加瓦。
此次获评不仅是对博沃生物在人用疫苗领域综合实力的认可，也是对博沃生物的创新意识、创新进步与创新成果的肯定。博沃生物将继续秉承“卓越、诚信、主动、分享、乐观”的核心价值观，以满足人民健康生活的美好愿景为己任，争取早日将自研产品投入市场，实现“为生命喝彩”的使命！
相关报道：
https://mp.weixin.qq.com/s/mnmukxapBhP6kQrR1WsE9w
Recently, the "2023 China Biomedical Science and Technology Innovation Value List" was officially released in Shanghai, China, BravoBio was awarded the title of "Top 10 Vaccine Enterprises with Most Growth Potential" for its outstanding innovation performances in research and development of high-end human vaccines.
The "2023 China Biomedical Science and Technology Innovation Value List" was jointly initiated by Shanghai Biopharmaceutics Industry Association and Yiyun Technology. Based on the growth criteria defined by Hua Yi Research Institute and questionnaire survey, interview, data collection and verification, the enterprises with most innovation value in the industry were selected, forming a list of objective evaluation from the third-party. This selection covered 12 biomedical industries including small-molecule innovative drug, biological drug, Chinese medicine, vaccine, cell gene therapy, innovative device, in vitro diagnostics, consumer medicine, digital healthcare, CXO, biomedical park, and financial services organization. Among them, the list of "Top 10 Vaccine Enterprises with Most Growth Potential" mainly focuses on the innovation value in traditional vaccines, recombinant protein vaccines, vector-based vaccines and nucleic acid vaccines. A group of vaccine companies with international influence and high growth potential are now contributing to the prevention and control of diseases in China and abroad.
This Honor is not only a recognition for our comprehensive strengths in human vaccine industry, but also an affirmation for our awareness, progress and achievement in vaccine innovation. BravoBio will continually adhere to the core values of "Best, Reliable, Active, Valuable, and Optimistic", hold the mission to improve the quality of people’s lives, push vaccine products into the market, realizing our dream of "Cheers to life"!
关于博沃生物
上海博沃生物科技有限公司（简称博沃生物）2011年3月成立于上海张江高科技园区，2021年10月迁至北上海生物医药园。2012年12月设立了武汉博沃，是国家级高新技术企业、中国疫苗行业协会理事单位。2020年公司被德勤Deloitte评为“中国明日之星”，是内地唯一获奖的生物医药企业。公司具有基因编辑/构建/克隆/检测、细菌大规模培养、细胞/病毒大规模培养、生物活性物质制备（多糖、蛋白质、病毒等）、多糖与蛋白质化学结合、新型佐剂、新型制剂、新型检测等多个先进技术平台，满足各类创新型生物医药特别是疫苗开发的需要。博沃生物以满足中国和世界人民健康生活的美好愿景为己任，致力于通过重磅级创新疫苗的开发和市场化运营，成为全球疾病控制领域的主力军。
Shanghai BravoBio Co., Ltd (BravoBio) was established in Zhangjiang Hi-Tech Park in Shanghai in March 2011 and moved to MediPark in North Shanghai in October 2021. Its subsidiary company, Wuhan BravoVax Co., Ltd (BravoVax), was founded in December 2012. BravoVax is a "state level high-tech enterprise" and a council member of China Association of Vaccines (CAV). It was awarded as "China Rising Star" by Deloitte in 2020, becoming the only biopharmaceutical enterprise in Chinese mainland to win this award. The company boasts a number of advanced technology platforms, including gene editing / construction / cloning / detection, large-scale bacterial / cell / virus culture, preparation of bioactive substances (polysaccharide, protein, virus, etc.), chemical combination of polysaccharide and protein, novel adjuvant, new preparation and analytical assays, etc. to meet the needs of developing innovative biologics, especially vaccines. BravoBio has held the mission to improve the quality of people's lives, aiming for a healthier and happier future. The company is active to be a global supplier of high-quality vaccine through development and commercialization of its innovative and blockbuster vaccines, contributing to the control of global diseases.
关注博沃生物
